Reply
Linda Henry
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
Inova Medicine, Inova Health System, Falls Church, Virginia, USA
Center for Outcomes Research in Liver Diseases, Washington, District of Columbia, USA
Search for more papers by this authorJames M. Paik
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
Inova Medicine, Inova Health System, Falls Church, Virginia, USA
Search for more papers by this authorCorresponding Author
Zobair M. Younossi
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
Inova Medicine, Inova Health System, Falls Church, Virginia, USA
Correspondence
Zobair M. Younossi, Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, 3300 Gallows Rd., Falls Church, VA 22042, USA.
Email: [email protected]
Search for more papers by this authorLinda Henry
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
Inova Medicine, Inova Health System, Falls Church, Virginia, USA
Center for Outcomes Research in Liver Diseases, Washington, District of Columbia, USA
Search for more papers by this authorJames M. Paik
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
Inova Medicine, Inova Health System, Falls Church, Virginia, USA
Search for more papers by this authorCorresponding Author
Zobair M. Younossi
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA
Inova Medicine, Inova Health System, Falls Church, Virginia, USA
Correspondence
Zobair M. Younossi, Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, 3300 Gallows Rd., Falls Church, VA 22042, USA.
Email: [email protected]
Search for more papers by this authorCONFLICT OF INTEREST
Dr. Younossi consults for Gilead, Viking, Siemens, Merck, and Madrigal.
REFERENCES
- 1Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic associated fatty liver disease? Hepatology. 2022. https://doi.org/10.1002/hep.32499
- 2Fouad Y, Abdel Dayem WA, Mehrez M. Letter to the editor: apples should be compared with apples. Hepatology. 2022. https://doi.org/10.1002/hep.32564
- 3Attia D, Gomaa A, Abdel Aleem S. Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology. 2022. https://doi.org/10.1002/hep.32563
- 4Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73(1): 202–9.
- 5Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019; 17(8): 1625–33.e1.
- 6Paik JM, Golabi P, Biswas R, Alqahtani S, Venkatesan C, Younossi ZM. Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States. Hepatol Commun. 2020; 4(6): 890–903.
- 7. Analytic and Reporting Guidelines: The National Health and Nutrition Examination Survey (NHANES). September 2006 [cited 2022 Apr 22]. Available from: http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf
- 8Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018; 97(13):e0214.
- 9Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017; 37(8): 1209–18.
- 10Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009–2019. J Hepatol. 2021; 75(4): 795–809.
